Oncoinvent ASA (KLDVK) - Total Liabilities
Based on the latest financial reports, Oncoinvent ASA (KLDVK) has total liabilities worth Nkr230.30 Million NOK (≈ $24.23 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See KLDVK working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Oncoinvent ASA - Total Liabilities Trend (2021–2025)
This chart illustrates how Oncoinvent ASA's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Oncoinvent ASA.
Oncoinvent ASA Competitors by Total Liabilities
The table below lists competitors of Oncoinvent ASA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Globe International Ltd
AU:GLB
|
Australia | AU$49.21 Million |
|
Micropolis Holding Company
NYSE MKT:MCRP
|
USA | $40.58 Million |
|
Samil Pharm
KO:000520
|
Korea | ₩226.31 Billion |
|
ZUARI INDUSTRIES LIMITED
NSE:ZUARIIND
|
India | Rs34.46 Billion |
|
Antalpha Platform Holding Co
NASDAQ:ANTA
|
USA | $997.99 Million |
|
Barington/Hilco Acquisition
NASDAQ:BHAC
|
USA | $9.74 Million |
|
DHI Group Inc
NYSE:DHX
|
USA | $95.20 Million |
|
Pylon Public Company Limited
BK:PYLON
|
Thailand | ฿467.28 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Oncoinvent ASA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See KLDVK equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.83 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oncoinvent ASA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oncoinvent ASA (2021–2025)
The table below shows the annual total liabilities of Oncoinvent ASA from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Nkr230.30 Million ≈ $24.23 Million |
+7.26% |
| 2024-12-31 | Nkr214.71 Million ≈ $22.59 Million |
+49.35% |
| 2023-12-31 | Nkr143.77 Million ≈ $15.13 Million |
+20.29% |
| 2022-12-31 | Nkr119.51 Million ≈ $12.58 Million |
+101.70% |
| 2021-12-31 | Nkr59.25 Million ≈ $6.24 Million |
-- |
About Oncoinvent ASA
Kaldvik AS engages in the salmon farming business in Iceland. It also operates smolt stations. The company was incorporated in 2020 and is headquartered in Eskifjörður, Iceland. Kaldvik AS was formerly known as Ice Fish Farm AS and changed its name to Kaldvik AS in August 2024. Kaldvik AS operates as a subsidiary of Austur Holding As.